Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

InMed Pharmaceuticals (INM) Assets (2021 - 2025)

Historic Assets for InMed Pharmaceuticals (INM) over the last 5 years, with Q3 2025 value amounting to $13.4 million.

  • InMed Pharmaceuticals' Assets rose 2767.27% to $13.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $13.4 million, marking a year-over-year increase of 2767.27%. This contributed to the annual value of $15.6 million for FY2025, which is 3177.98% up from last year.
  • InMed Pharmaceuticals' Assets amounted to $13.4 million in Q3 2025, which was up 2767.27% from $15.6 million recorded in Q2 2025.
  • Over the past 5 years, InMed Pharmaceuticals' Assets peaked at $19.4 million during Q4 2021, and registered a low of $8.5 million during Q4 2024.
  • In the last 5 years, InMed Pharmaceuticals' Assets had a median value of $14.1 million in 2023 and averaged $13.8 million.
  • Per our database at Business Quant, InMed Pharmaceuticals' Assets crashed by 4426.72% in 2024 and then soared by 3177.98% in 2025.
  • InMed Pharmaceuticals' Assets (Quarter) stood at $19.4 million in 2021, then fell by 12.71% to $16.9 million in 2022, then fell by 9.84% to $15.3 million in 2023, then tumbled by 44.27% to $8.5 million in 2024, then soared by 57.15% to $13.4 million in 2025.
  • Its Assets was $13.4 million in Q3 2025, compared to $15.6 million in Q2 2025 and $9.3 million in Q1 2025.